NasdaqGS:NBIXBiotechs
Neurocrine Biosciences Enters New Growth Phase With Broader Revenue Mix
Neurocrine Biosciences (NasdaqGS:NBIX) is rolling out new products, including Chronesity and CRENESSITY, alongside a broad set of pipeline updates.
The company reports strong early adoption for both launches, with CRENESSITY expected to reach blockbuster levels over time.
Late stage clinical programs in neuropsychiatry and metabolic diseases are expanding, supported by a build out of the sales force and commercial capabilities.
For you as an investor, the key point is that Neurocrine...